Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Spring on the Road
Spring Wellness
Premier Home Stylle Tour 2024
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Coherus BioSciences, Inc.
< Previous
1
2
Next >
Coherus Applauds Congressional Designation of September 30th as Rare Cancer Day
October 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Announces Three Presentations at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
September 27, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
FDA Issues Complete Response Letter (CRL) for UDENYCA® ONBODY™ Biologics License Application Solely Due to an Ongoing Review of Inspection Findings at a Third-Party Filler; Coherus Also Announces Completion of Toripalimab FDA Inspections
September 25, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Announces New Employment Inducement Grants
September 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Completes Surface Oncology Acquisition
September 08, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences to Participate at Upcoming September Investor Conferences
September 01, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Announces New Employment Inducement Grants
August 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
August 02, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences to Report Second Quarter 2023 Financial Results on August 02, 2023
July 26, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Announces New Employment Inducement Grants
July 21, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Appoints Dr. Michael Ryan to its Board of Directors
July 20, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus and Superior Biologics Announce National Distribution Agreement for YUSIMRY™
July 13, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
July 03, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Announces Positive Final Overall Survival Results of JUPITER-02 Phase 3 Trial Evaluating Toripalimab in Nasopharyngeal Carcinoma
June 05, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Mark Cuban Cost Plus Drug Company joins forces with Coherus to make YUSIMRY™, a HUMIRA® biosimilar, available to patients
June 01, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Announces Industry-Wide Lowest List Price for Adalimumab Biosimilar YUSIMRY™ (adalimumab-aqvh) Launching in July 2023
June 01, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Announces U.S. Launch of UDENYCA® Autoinjector
May 22, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Prices Public Offering of Common Stock
May 16, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Announces Proposed Public Offering of Common Stock
May 15, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
May 08, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences to Present at Upcoming Investor Conferences in May
May 04, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences to Report First Quarter 2023 Financial Results on May 8, 2023
May 01, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus and Junshi Biosciences Announce Toripalimab Studies to be Presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Reports Fourth Quarter and Full Year 2022 Results
March 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
FDA Approves UDENYCA® Autoinjector
March 06, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences to Present at Upcoming Investor Conferences in March
March 01, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023
February 28, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus Granted Permanent, Product-Specific Q-Code for CIMERLI® (ranibizumab-eqrn) from the Centers for Medicare and Medicaid Services
February 13, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus BioSciences Announces New Employment Inducement Grants
February 03, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
Coherus and Junshi Biosciences Announce Positive Final Overall Survival Results of JUPITER-02, a Phase 3 Clinical Trial Evaluating Toripalimab as Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma
February 15, 2023
From
Coherus BioSciences, Inc.
Via
GlobeNewswire
Tickers
CHRS
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.